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1. Introduction 
It has been known for a number of years that many patients with ovarian cancer suffer an 
accumulation of ascites fluid that contains a factor which supports the intraperitoneal 
growth of ovarian cancer cells (Mills et al. 1990). Following from the identification of 
lysophosphatidic acid (LPA) as a major growth factor in serum (van Corven et al. 1989), 
LPA was identified as the major “ovarian cancer activating factor” in ascites fluid (Xu et al. 
1995). LPA was shown to accumulate to high concentrations (up to 80 µM) in ascites fluid.   
Since then, numerous publications have demonstrated the role of LPA in several biological 
processes relevant to cancer including cell migration and invasion, inhibition of apoptosis 
and senescence, angiogenesis and chemoresistance. Increases in plasma LPA are also being 
considered as a diagnostic biomarker of ovarian cancer (e.g. (Bese et al. 2010)). It is perhaps 
surprising then, that compounds interfering with this pathway have made slow progress to 
the clinic. Part of the reason for this likely reflects the complexity of the LPA signalling 
pathway. However, recent work has delineated many of the enzymes and receptors 
involved in regulating the LPA signalling pathways, revealing complexity in different LPA 
species, in the pathways involved in the metabolism of LPA, in LPA receptors and finally in 
the (patho)physiological responses to LPA. An understanding of how these pathways are 
deregulated in ovarian cancer has begun to suggest potential targets for the development of 
therapeutic drugs. One such target is autotaxin, an enzyme involved in the synthesis of 
LPA.  Recently, several crystal structures of autotaxin have been solved, and these provide 
powerful tools to aid the development of autotaxin inhibitors. However, to fully appreciate 
the potential of autotaxin as a drug target, we first review LPA signalling pathways. 
2. The LPA signalling pathway 
2.1 Complexity in LPA 
LPA (Fig. 1) itself provides a first example of complexity in this pathway, as it comprises a 
family of molecules. In general, LPA consists of a glycerol moiety linked as an ester to 
phosphate and fatty acid moieties. However, LPA molecules may differ in the length and 
the degree of unsaturation of the fatty acid, and the fatty acid may be attached to the sn1 or 
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sn2 positions on the glycerol. In some cases, the fatty acid is replaced by an alkyl chain 
attached via an ether linkage. The phosphate may be attached to both the second and third 
glycerol hydroxyl groups, forming a cyclophosphate. 
 
 
Fig. 1. A Lysophosphatidic acid is comprised of fatty acid, glycerol and phosphate moieties. 
B. Principle routes to the biosynthesis of LPA. ATX, autotaxin; PLA2, phospholipase A2. 
Note that autotaxin behaves as a phosopholipase D that uses lyso substrates, i.e. those 
lacking one fatty acid attached to the glycerol. 
2.2 Complexity in the synthesis of LPA 
There are a number of enzymes which can catalyze the synthesis of  LPA in ovarian cancer 
and it is becoming more clear which of these contribute to the accumulation of LPA in 
ovarian cancer. LPA is synthesized both intracellularly and extracellularly, by ovarian 
cancer cells as well as mesothelial cells. Autotaxin is a secreted phospholipase that catalyses 
the hydrolysis of lysophosphatidyl choline to produce LPA and choline (fig. 2). Increased 
expression of autotaxin is observed in several cancers including renal (Stassar et al. 2001), 
thyroid (Kehlen et al. 2004), glioblastoma (Hoelzinger et al. 2005; Kishi et al. 2006), follicular 
lymphoma (Masuda et al. 2008), hepatic (Wu et al. 2010), prostate (Nouh et al. 2009) and  
pancreatic cancer (Nakai et al. 2011). Autotaxin expression is also increased in 
chemoresistant ovarian cancer compared to chemosensitive disease (Jazaeri et al. 2005). 
Ectopic expression of autotaxin in mammary epithelium is sufficient to cause high 
frequency breast cancer (Liu et al. 2009).  Together these observations point to role for 
autotaxin in several cancer types. The elevated levels of LPA observed in ascites obtained 
from patients with ovarian cancer suggests a role in ovarian cancer. The increase in LPA 
levels are accompanied by elevated LPC, the substrate of autotaxin (Liu et al. 2009). 
Autotaxin itself is also present in ascites fluid (Tokumura et al. 2007).  Although transgenic 
mice lacking autotaxin die as embryos, heterozygotes with one functional allele encoding 
autotaxin show a 50% reduction in plasma LPA (Tanaka et al. 2006), suggesting that 
autotaxin is the enzyme primarily responsible for the synthesis of LPA in plasma. However, 
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it remains a possibility that autotaxin is not the enzyme responsible for the accumulation of 
LPA observed in ovarian cancer. In addition to autotaxin, extracellular LPA could 
potentially also be derived from the hydrolysis of phosphatidic acid by secreted 
phospholipase A2 (sPLA2). 
A number of intracellular enzymes including glycerol 3-phosphate fatty acid transferase 
(GPFAT) and phospholipase D (PLD) and phospholipase A2 may also contribute to the 
production of LPA at the cell membrane. It is possible that intracellular enzymes contribute 
to the accumulation of extracellular LPA. Although GPFAT has not received much attention 
in ovarian cancer, PLD2 has recently been shown to contribute to EGF-induced LPA 
production (Snider et al. 2010).  Other potential sources of LPA include intracellular 
isoforms of phospholipase A2 which use phosphatidic acid as a substrate (Fig. 1). cPLA2 is a 
calcium-dependant phospholipase implicated in cell migration whereas iPLA2 is a calcium-
independent phospholipase. Which cells are the potential sources of LPA? Platelets have 
previously been shown to be an important source of LPA in serum (Boucharaba et al. 2004), 
and Xu and co-workers have clearly shown in a murine model of ovarian cancer that both 
host and tumor cells contribute to the formation of LPA in ascites and this is catalysed by 
iPLA2 (Li et al. 2010).  Peritoneal mesothelial cells are one potential source of extracellular 
LPA produced by PLA2 (Ren et al. 2006). 
If both host and tumor cells contribute to the accumulation of peritoneal LPA, and there are 
several pathways capable of contributing to the formation of LPA, it seems reasonable to ask 
whether animal models accurately reflect clinical reality. In xenograft studies it is common 
to implant a human tumor cell into a murine host. Is the relative contribution of different 
LPA biosynthetic pathways in xenograft studies quantitatively similar to that observed in 
ovarian cancer? This is important because the relative contribution of, e.g., autotaxin and 
iPLA2 to the generation of LPA will likely influence the success of inhibitors of these 
individual enzymes when used in patients. Thus, we consider that although preclincial 
experiments may continue to shed light on validity of the different LPA biosynthetic 
pathways as drug targets, a definitive answer will only be provided by clinical studies. 
The concentration of LPA in ascites fluid is controlled by its rate of elimination as well as its 
rate of synthesis. It is important, therefore, to consider also pathways of LPA catabolism. 
Two lipid phosphatases, LPP1 and LPP3, have been implicated in the hydrolysis of LPA. 
Importantly, LPP1 shows reduced expression in ovarian cancer cells, suggesting that this 
might contribute to increased levels of LPA (Tanyi et al. 2003; Tanyi et al. 2003).  
Correspondingly, expression of these genes has been shown to inhibit several of the 
responses ascribed to LPA, for example colony formation and cell migration. Understanding 
the pathways that regulate the expression of these phosphatases is important, as it might 
provide targets which can be used to increase the expression of LPP1 or LPP3 and so 
develop drugs to increase LPA catabolism. 
It is also worth considering how the expression of LPA anabolic and catabolic enzymes 
might vary between patients as this may influence the design of clinical trials. Although we 
await further data to address this, it is worth considering the potential impact on the clinical 
use of drugs regulating the LPA pathway. It seems that it will be appropriate to select 
patients most likely to benefit from a particular enzyme inhibitor taking into account which 
biosynthetic pathways are deregulated. For example, PLD2 has been implicated in EGF-
driven LPA production (Snider et al. 2010), so patients whose tumors are driven by the EGF 
pathway may be more dependent on PLD2 than other LPA producing enzymes. Similarly, 
VEGF regulates autotaxin production (see below), so tumors in which VEGF production is 
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substantially elevated may be more dependent on autotaxin for LPA production. The 
expression level of LPP1 or LPP3 may also influence the response to drugs inhibiting the 
production of LPA. We speculate that inter-patient variability in the enzymes catalysing 
LPA catabolism may lead to different response to drugs which inhibit LPA synthesis and 
evaluating the extent of any clinical variation may prove to be important. 
2.3 Complexity in LPA receptors 
Two classes of cell surface receptors for LPA have been described, all of which are G-protein 
coupled receptors (Tigyi 2010). The first of these classes comprise the receptors LPA1, LPA2 
and LPA3. These are closely related and form part of the EDG (endothelial differentiation 
gene) family of receptors which also includes receptors for the bioactive lipid sphingosine 1-
phosphate (S1P). At high (µM) concentrations, LPA may also bind to S1P receptors. A 
second set of LPA receptors are more closely related to purinergic receptors including LPA4 
(also known as P2Y9), LPA5 (GPR95). There are several additional receptors that are also 
reported to respond to LPA including GPR35, GPR87, P2Y5 and P2Y10 and further 
characterization of these is on-going. Clearly, it is important to consider which of these 
receptors should be exploited as drug targets in ovarian cancer. 
LPA2 and LPA3 appear to promote ovarian tumorigenesis. The expression of LPA2 and LPA3 
is increased in ovarian cancer, (Fang et al. 2002; Wang et al. 2007; Murph et al. 2008) and 
over- expression of these receptors in Sk-Ov-3 cells promotes growth of primary tumors and 
metastasis (Yu et al. 2008). In clinical samples, expression of LPA2 and LPA3 correlates with 
tumor stage (Wang et al. 2007). In contrast, the expression of LPA1 is decreased in ovarian 
cancer and expression of LPA1 promotes apoptosis (Furui et al. 1999). These observations 
are important from a therapeutic perspective, because it suggest that ovarian cancer patients 
might benefit from a drug which is an LPA2, LPA3 antagonist but it may be preferable that 
such a drug does not bind with high affinity to LPA1. However, it should be noted that the 
growth inhibitory properties of LPA1 were found to be independent of LPA (Furui et al. 
1999) and encouraging results have already been obtained with a pan-LPA receptor 
antagonist in xenograft studies (Zhang et al. 2009). We already have substantial experience 
developing (non-oncological) drugs using G-protein coupled receptors as drug targets, 
suggesting this may be a fruitful avenue for therapeutic research. 
As well as binding to cell surface receptors, LPA has been proposed to activate the nuclear 
hormone receptor PPAR┛. These intracellular receptors function as transcription factors and 
drive the expression of genes involved in diverse physiological responses including glucose 
and lipid metabolism, inflammatory response and apoptosis. PPAR┛ is over-expressed in 
ovarian cancer (Zhang et al. 2005) and its expression is associated with a poor response to 
chemotherapy and shortened survival (Davidson et al. 2009). Although this might lead to 
the hypothesis that activation of PPAR┛ by LPA is tumorigenic, confusingly synthetic PPAR 
agonists (the “glitazones”) inhibit the proliferation of ovarian cancer cells and induce 
apoptosis (Yang et al. 2007). Glitazones also display synergistic activity with platinum 
chemotherapy through down-regulation of metallothionines involved in the detoxification 
of platinum (Girnun et al. 2007).  Thus, the contribution of the activation of PPAR┛ by LPA 
to ovarian tumorigenesis remains to be further clarified. 
Finally, it has also been pointed out that LPA binds to a number of intracellular 
cytoskeletal proteins (Tigyi 2010) possibly reflecting an  intracellular role for LPA in 
regulating cell migration.  
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3. Physiological and pathophysiological functions of LPA 
3.1 LPA/autotaxin and migration and invasion 
LPA has several well characterized effects upon ovarian cancer cell migration and 
invasion. Firstly, activation of Src kinase by LPA leads to the breakdown of cell-cell 
junctions, promoting cell scattering (Huang et al. 2008). The breakdown of cell junctions is 
facilitated by activation uPA (urokinase plasminogen activator) by LPA, which leads to 
proteolysis of E-cadherin. Secondly, LPA triggers cytoskeletal reorganization (Do et al. 
2007; Kim et al. 2011) and reorganization of cell contacts with the extracellular matrix 
which promotes cell motility (Sawada et al. 2002; Bian et al. 2004; Bian et al. 2006). 
Thirdly, LPA induces the expression of several proteases including uPA (Pustilnik et al. 
1999; Li et al. 2005), MMP1 (Wang et al. 2011), MMP2 (Fishman et al. 2001) MMP7 and 
MMP9 (Park et al. 2011) which contribute to the breakdown of extracellular matrix 
allowing invasion through basement membrane. In addition, LPA decreases expression of 
TIMP metalloprotease inhibitors (Sengupta et al. 2007), thereby potentiating the effect of 
activation of proteases. 
Although the role of autotaxin in migration and invasion has not yet been studied in ovarian 
cancer to the same level of detail as in other cancers, the role of autotaxin in these processes 
is well founded. Indeed, autotaxin was first identified through its activity as an autocrine 
motility factor (Stracke et al. 1992) and integrin ┙6┚4, which is associated with and invasive 
phenotype, can increase the expression of autotaxin (Chen and O'Connor 2005). Autotaxin 
and LPA promote the expression of the extracellular matrix protein osteopontin which 
promotes migration (Zhang et al. 2011). Autotaxin activates the small G-proteins cdc42 and 
Rac (Jung et al. 2002; Hoelzinger et al. 2008; Harper et al. 2010) and focal adhesion kinase 
(Jung et al. 2002), proteins which are key regulators of cell motility. More direct evidence 
comes from the observation that knockdown of autotaxin inhibits cell migration in several 
cancer types  (Kishi et al. 2006; Gaetano et al. 2009; Harper et al. 2010) and over-expression 
of autotaxin increases motility (Kishi et al. 2006; Harper et al. 2010). Autotaxin regulates the 
formation of invadopodia (Harper et al. 2010) and induces the expression of uPA (Lee et al. 
2006) and MMP3 (Haga et al. 2009). Correspondingly, knockdown of autotaxin inhibits 
invasion (Hoelzinger et al. 2008) while over-expression promotes invasion (Nam et al. 2000; 
Yang et al. 2002). Finally, autotaxin promotes osteolytic bone metastases derived from breast 
cancer cells (David et al. 2010).  Taken together, these observations suggest that LPA and 
autotaxin are likely to promote an invasive phenotype in ovarian cancer cells.  We discuss 
below the therapeutic implications of these observations. 
3.2 LPA/autotaxin and a supportive microenvironment 
LPA contributes to providing a microenvironment that is conducive to tumor growth. It 
does this in part by supressing apoptosis and senescence.  LPA is itself a growth factor (van 
Corven et al. 1989) for several cell types. It stimulates the growth of cultures of ovarian 
cancer cells (Xu et al. 1995; Hu et al. 2003) by several pathways  (Hurst and Hooks 2009). It 
also induces the expression of the growth factor Gro┙ (Lee et al. 2006). Finally,  iPLA2, one 
of the enzymes involved in the synthesis of LPA, can promote cell cycle progression in the 
absence of exogenous growth factors (Song et al. 2007).  
LPA induces the production of the major angiogenic factor VEGF by ovarian cancer cells 
(Hu et al. 2001) and mesenchymal stem cells (Jeon et al. 2010). LPA also increases VEGF 
receptor expression on endothelial cells. The effect of LPA is apparently amplified by VEGF-
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induced expression of autotaxin by ovarian cancer cells (Ptaszynska et al. 2008) and 
endothelial cells (Ptaszynska et al. 2010) thereby potentiating LPA production. LPA also 
promotes the expression of other pro-angiogenic factors including IL-8 by tumor cells and 
SDF-1 by mesenchymal stem cells (Jeon et al. 2010). These observations suggest a key role 
for autotaxin and LPA in ovarian cancer driven angiogenesis and have led to the suggestion 
that autotaxin may also be a therapeutic target for inhibiting angiogenesis (Ptaszynska et al. 
2010). In addition to its role in angiogenesis VEGF has also been implicated in LPA induced 
invasion (So et al. 2005; Wang et al. 2009; Wang et al. 2011). 
3.3 LPA/autotaxin and inhibition of apoptosis and chemoresistance 
The potential contribution of LPA to resistance to chemotherapy is of considerable 
therapeutic significance. Patients with ovarian cancer often receive chemotherapy 
comprising a taxane and a platinum-based compound, often paclitaxel and carboplatin. 
Although these drugs are initially effective, many patients eventually relapse with a disease 
that has become resistant to chemotherapy. Thus, a key reason that approximately  30% of 
patients diagnosed with ovarian cancer survive only 5-years post-diagnosis is the 
development of drug resistance. Understanding the molecular basis of drug resistance and 
developing drugs which restore drug sensitivity is one strategy to improve the treatment of 
ovarian cancer. 
LPA causes the translocation of the pro-apoptotic receptor Fas from the cell surface, making 
tumor cells less responsive to stimuli that activate the extrinsic apoptosis pathway (Meng et 
al. 2005).  Fas activates an intracellular caspase protease cascade to drive apoptosis. cFLIP is 
an inhibitor of caspase-8 activation, and the increased expression of cFLIP that is induced by 
LPA further contributes to suppression of apoptosis by LPA (Kang et al. 2004). At the same 
time, LPA induces the expression of Fas ligand (FasL) on tumor cells, and this promotes 
apoptosis of lymphocytes (Meng et al. 2004; Meng et al. 2005) presumably allowing tumor 
cells to avoid immune surveillance. LPA also increases the expression of the survival factor 
GEP (Kamrava et al. 2005). LPA inhibits the intrinsic apoptosis pathway by promoting 
phosphorylation of the pro-apoptotic protein BAD (Kang et al. 2004), which prevents BAD 
from promoting apoptosis through activation of Bak and Bax and permeabilization of the 
mitochondrial outer membrane. These observations suggest that LPA can regulate both the 
intrinsic and extrinsic apoptosis pathways, underlining the importance of this pathway as a 
therapeutic target. 
In addition to LPA, there is evidence directly linking autotaxin to cell survival. Expression of 
autotaxin suppresses apoptosis in response to serum starvation (Song et al. 2005). LPA has 
been shown to activate the PI 3-kinase/Akt pathway in several cell types, including in 
ovarian cancer cells (Baudhuin et al. 2002). This pathway is a well described cell survival 
pathway and contributes to LPA suppressing both the extrinsic and the intrinsic apoptosis 
pathways (Kang et al. 2004). Similarly, inhibition of apoptosis by autotaxin is dependent on 
the PI 3-kinase pathway (Song et al. 2005). 
As well as inhibition of apoptosis, one of the hallmarks of cancer is the avoidance of 
senescence. LPA suppresses p53-dependant replicative senescence (Kortlever et al. 2008), at 
least in part through induction of telomerase (Bermudez et al. 2007; Yang et al. 2008). 
Along with many other chemotherapeutic agents, carboplatin and paclitaxel induce 
apoptosis.  It seems reasonable to presume that the ability of autotaxin and LPA to suppress 
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apoptosis contributes to resistance to paclitaxel and carboplatin.  As these drugs are the 
cornerstone of ovarian cancer chemotherapy, the potential of the LPA pathway as a 
therapeutic target is again underlined. Early work demonstrated that LPA confers resistance 
to cisplatin (Frankel and Mills 1996) and this has also been observed in colon cancer cells 
(Sun et al. 2009). We conducted a screen to identify genes that confer resistance to 
carboplatin, and one of the hits identified in that screen was autotaxin. Expression of 
autotaxin delayed apoptosis induced by carboplatin, while apoptosis was accelerated after 
inhibition of autotaxin by either siRNA or with a small molecule inhibitor (Vidot et al. 2010). 
More recently, LPA and autotaxin have been shown to confer resistance of breast and 
melanoma cancer cells to paclitaxel (Samadi et al. 2009). Resistance to paclitaxel depends on 
PI 3-kinase, presumably reflecting the role of PI 3-kinase downstream of LPA in survival 
signalling that was noted above. Remarkably, resistance to paclitaxel conferred by LPA by 
restores normal spindle function in cells exposed to paclitaxel and the cells escape M-phase 
arrest (Samadi et al. 2011). The LPA2 receptor is one candidate for mediating 
chemoresistance, because LPA2-/- mice exhibit increased radiation-induced apoptosis (Deng 
et al. 2007). Thus, there is direct evidence linking autotaxin to resistance to both 
chemotherapeutic agents used to treat ovarian cancer. 
Other proteins in the LPA pathway may also contribute to chemoresistance. RGS proteins 
(Regulator of G-protein signalling) attenuate signalling by LPA receptors by increasing the 
GTPase activity of G-proteins that are activated by LPA receptors (Hurst et al. 2008). 
Expression of several RGS proteins is decreased in ovarian cancer cell lines that are resistant 
to cisplatin (Hooks et al. 2010). Knockdown of expression of two RGS protein, RGS10 and 
RGS17, causes a 2-3 fold reduction in the potency but a striking 6-fold reduction in cisplatin 
potency is observed when the expression of both RGS proteins is inhibited. This suggests 
that loss of expression of RGS proteins, leading to increased activity of LPA receptor 
signalling through G-proteins, may contribute to resistance to chemotherapy.  
In addition to inhibiting apoptosis through G-protein signalling, the LPA2 receptor also 
regulates the pro-apoptotic protein Siva-1.  Activation of p53 following DNA damage 
increases the expression of pro-apoptotic Siva-1 and this contributes to cisplatin-induced 
apoptosis (Barkinge et al. 2009), as well apoptosis induced by uvltraviolet light (Chu et al. 
2004). LPA causes ubiquitination and turnover of Siva-1 and this contributes to 
suppression of apoptosis by LPA (Lin et al. 2007). This may be mediated by the LPA2 
receptor.  LPA2 is distinct from other LPA receptors in containing zinc finger and a C-
terminal PDZ binding motifs.  These motifs serve to recruit NHERF2 and TRIP6, which 
form a ternary complex with Siva-1. Both NHERF2 and TRIP6 are required for LPA to 
confer resistance to cisplatin (E et al. 2009). But how does Siva-1 induce apoptosis? In part, 
this probably reflects inhibition of the cell survival driven by the transcription factor 
NFB.  Intriguingly, Siva-1 can also inhibit Bcl-XL, a member of the anti-apoptotic Bcl-2 
family proteins that suppress activation of Bak and Bax in the intrinsic apoptosis pathway 
(Xue et al. 2002). We have shown previously that inhibition of Bcl-XL increases sensitivity 
to carboplatin (Witham et al. 2007). Together with our observation that autotaxin confers 
resistance to carboplatin (Vidot et al. 2010), these data suggest that autotaxin may confer 
resistance to carboplatin by suppressing the intrinsic apoptosis pathway (fig. 2). As we 
discuss below, this predicts that autotaxin inhibitors may be useful in the treatment of 
drug-resistant ovarian cancer. 
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Fig. 2. Regulation of chemoresistance by LPA and autotaxin. CTX denotes chemotherapy, 
PI-3K, PI 3-kinse. 
The observation that RGS and Siva pathways both contribute to chemoresistance in different 
cell lines highlights the point that there are multiple mechanisms that can cause drug 
resistance. Thus, if the signalling pathways that are activated by LPA receptors are used as 
therapeutic targets to restore chemosensitivity, it may be necessary to develop several different 
therapeutic agents and use them in accordance with the particular pathway that is driving 
chemoresistance in a individual patient’s tumor. If multiple pathways promote resistance, 
several drugs may be necessary.  Alternatively, it may be more straight forwards to develop 
drugs which either inhibit the LPA receptor(s) or prevent the production of LPA itself.  
As well as contributing to resistance to chemotherapy, autotaxin also confer resistance to 
histone deacetylase inhibitors. HDAC3 and HDAC7 repress the expression of autotaxin. 
Consequently, exposure to the HDAC inhibitor trichostatin (TSA) increases the expression 
of autotaxin and the subsequent production of LPA inhibits apoptosis induced by TSA. This 
suggests that autotaxin confers resistance to HDAC inhibitors (Li et al. 2011). One clinical 
use of autotaxin inhibitors may be in combination with HDAC inhibitors. 
4. Is autotaxin a valid target in ovarian cancer? 
A starting point for drug discovery is “target validation” – a process in which data is 
amassed to give confidence that inhibiting a particular drug target will afford the desired 
therapeutic outcome. The foregoing discussion highlights several points in the LPA 
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signalling pathway which might provide drug targets to treat ovarian cancer. Drugs could 
be developed which: inhibit the synthesis of LPA; increase the catabolism of LPA; up-
regulate LPA binding proteins to sequester LPA; inhibit LPA binding to its receptors or 
inhibit LPA receptor expression; inhibit downstream signalling. (Note that strategies to 
modulate the tumor environment are already being explored as inhibitors of the VEGF 
pathway, e.g. bevacizumab, are currently in clinical trials in ovarian cancer and encouraging 
results have been obtained.) 
Although several of these approaches are feasible, in several cases we consider that there is 
currently insufficient data to identify a drug target as well validated in ovarian cancer.  For 
example, there are multiple signalling pathways activated by LPA receptors. Although 
experimental data is accumulating, several potential drug targets in these signalling 
pathways activated by LPA receptors require validation in additional cell lines and 
evaluation in clinical samples. Until such data is forthcoming, we consider that developing 
drugs which inhibit the synthesis of LPA or which inhibit LPA receptors are currently the 
most promising avenues. As we have discussed, there are difficulties with these approaches 
too. The complexity of the LPA pathway suggests to us that it may be difficult to gather 
robust target validation data with preclinical studies alone, and that well designed clinical 
research with inhibitors of autotaxin, iPLA2 or LPA receptors will be necessary to confirm 
the best approach(s). Thus, for the remainder of this review we will focus on autotaxin as 
one potential target to inhibiting the LPA pathway. 
5. Current status of autotaxin inhibitors 
To date a number of metal chelators, lipid analogues and non-lipid small molecules have 
been discovered to be inhibitors of autotaxin. In this section we have concentrated on recent 
reports of small molecule inhibitors of autotaxin. 
Cui and Macdonald have developed a series of tyrosine-derived ┚-hydroxyphosphonates as 
analogues of LPA that display activity as inhibitors of autotaxin (Cui et al. 2007; Cui et al. 
2008). The synthesis of this series of compounds is highlighted in Figure 3. The sodium 
borohydride reduction step gave rise to a mixture of two diasteroisomeric products that 
were separated and isolated by column chromatography. In the initial publications (Cui et 
al. 2007; Cui et al. 2008) the relative stereochemistry at the new chiral centre had not been 
determined, but later work from this group on a more advanced series of inhibitors gave 
insight to the relationship between stereochemistry and activity in the lead compounds (East 
et al. 2010). From an initial series of targets prepared (R1 = C15H31, variation of R2), the most 
active compound to be identified was compound 1a, derived from S-tyrosine and later 
confirmed to have the relative stereochemistry shown (Fig. 3), which was able to inhibit 73% 
of autotaxin activity when tested at a concentration of 1 µM. The syn isomer, 1b, was less 
active achieving 37% inhibition at the same concentration. Interestingly, the corresponding 
isomers of compound 1 prepared from the enantiomer R-tyrosine did not show potent 
inhibition of autotaxin even though they contained the same pyridyl subunit. Structural 
modification based around varying the length of, or incorporation of unsaturation into, the 
lipophilic side chains (R1, Fig. 3) of compounds 1a and 1b did not result in an increase in 
activity from that originally seen with 1a.  
In a follow-up study (East et al. 2010) the SAR of the pyridyl region was further explored 
and important structural features were determined to be: the nitrogen heteroatom, the 
presence of the methoxy substituent, the presence of methyl groups. Extending the alkyl 
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chain of the alkyloxy substituent to ethyl or propyl led to a fall in activity. Activity was 
retained on removing the heteroatom as long as the methoxy group and methyl substitution 
were also retained. In all cases the anti-isomer was more active than the syn isomer.  
Docking studies were carried out on compound 1a and suggested the proximity of the 
phosphonate to the two zinc centres at the active site and that the lipophilic side chain was 
able to fill a large lipophilic pocket, thought to bind the lipid tail of LPC. An aromatic-
guanidine binding interaction was also suggested between the benzyl substituent and Arg456 
and a weak H-bonding interaction between the methoxy substituent and Lys209 within the 
hydrophilic leaving group pocket of autotaxin. The degree of interaction was dependent upon 
the electron density of the aryl ring, with more electron rich substituents on the pyridyl ring 
favouring the interaction. Interestingly the aromatic ring of the tyrosine unit appeared to act 
solely as an appropriate spacer unit between the more important pharmacophore groups. 
 
 
Fig. 3. Tyrosine based inhibitors of autotaxin. (i) Acid chloride, Et3N, DCM, 0 oC, 3 h; (ii) 
Appropriate mesylate, K2CO3, 18-crown-6, acetone, reflux, overnight; (iii) n-BuLi, dimethyl 
methylphosphonate, -78 oC, 3 h; (iv) NaBH4, THF, EtOH, 0 oC, 2 h; (v) TMSBr, pyridine, 
DCM, rt, 4 h, then H2O/MeOH overnight. 
A study by Ovaa and co-workers (Albers et al. 2010; Albers et al. 2010) on a collection of ca. 
40,000 compounds has allowed the identification of a group of thiazolidinediones as 
autotaxin inhibitors. The general class of compound was prepared as outlined in Figure 4. 
From the initial screen, compound 2 was found to be the most active (IC50 = 56nM) and was 
selected for further optimization. Although structural variation at the benzylidene and 
benzyl groups did not lead to an increase in activity, the opportunity was taken to 
investigate pharmacophoric variation of the carboxylic acid substituent.  
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Fig. 4. (i) KOH, DMSO, appropriate benzyl bromide (as methyl ester), rt, 30 min; (ii) NaOH, 
DMSO/H2O, reflux, 4 h, 91% yield; (iii) NaH, DMF, rt, appropriate benzyl chloride, 22 h, 
74% yield; (iv) piperidine, EtOH, reflux, 20 h, 63% yield. 
Replacing this group with a boronic acid moiety gave compound 3 that was found to be a 
potent inhibitor of autotaxin both in vitro and in vivo (IC50 = 6 nM).  These results were 
rationalized on the basis that since the carboxylic acid group in 2 was expected to bind close 
to the active site threonine (Thr210) in autotaxin, a boronic acid moiety might be expected to 
do the same. There was a precedent for this since the proteasome inhibitor bortezomib binds 
to a threonine oxygen nucleophile at the active site through a boronic acid group (Groll et al. 
2006). The boronic acid-based thiazolidinediones showed greater affinity for autotaxin and 
are expected to show improved selectivity over other hydrolytic enzymes. The boronic acids 
such as 3 are expected to have the same binding site as the original lead 2, but they show 
mixed-type inhibition rather than the competitive inhibition displayed by 2. Ovaa has 
recently extended this work and has reported that the imidazolidine analogues such as 3b 
show a similar level of activity to 3a (Albers et al. 2011). 
Virtual screening techniques have been used by Parrill, Baker and co-workers (Parrill et al. 
2008; Hoeglund et al. 2010; Hoeglund et al. 2010; North et al. 2010). This has led to series of 
autotaxin inhibitors with pipemidic acid or  pthalimide cores and related compounds (fig. 
5). Of the pipemidic acid-based inhibitors (eg 4, 5, fig. 5),  compound 4 (IC50 = 1.6 µM) was 
used as a lead to investigate the activity of a range of analogues with varying substitution 
on the pendent benzene ring. The synthetic approach was straightforward (fig. 6), starting 
with commercially available pipemidic acid and a range of substituted phenyl 
isothiocyanates to produce 30 compounds for evaluation. Themes to emerge were that meta 
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substitution is preferred regardless of substituent, suggesting steric or conformational 
preferences rather than electronic effects are playing a role here. Within the meta class of 
compounds, inhibition was improved in the order: OMe<F<Cl<I,<CF3, reflecting neither 
size nor electronic trends. A single meta-trifluoromethyl group was preferred over two, and 
the singly substituted compound showed three times greater affinity for the enzyme than 
the original lead compound 4. Of the compounds screened, compound 7 emerged as the 




Fig. 5. Hits identified by virtual screening by Parrill and co-workers all of which inhibited 




Fig. 6. Synthesis of autotaxin inhibitors basded on pipemidic acid. Compound 7 was the 
most potent analog reported (IC50 ~ 1 µM). 
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The phthalimide-derived small molecule lead inhibitors that were identified in the virtual 
screen by the Parrill and co-workers were also further evaluated including some dimeric 
examples, (Fig. 7) (Hoeglund et al. 2010). It is noticeable that these compounds contain 
terminal functionality that would be expected to contribute towards binding to zinc at the 
active site. Compounds 8 and 10 showed mixed-mode inhibition, whereas compound 9 
showed competitive inhibition of autotaxin. 
 
 
Fig. 7. Phthalimide-derived autotaxin inhibitors, all of which showed moderate  potency  
(IC50 =  5 - 10µM) against autotaxin. 
A recent report by Miller and Tigyi (Gupte et al. 2011) has built upon work carried out by 
Ferry and co-workers reporting that compound 11 (known as S32826, fig. 8; (Ferry et al. 
2008)) possessed nanomolar activity as an autotaxin inhibitor.  S32826 was inactive when 
evaluated using in vivo systems, and it has been presumed by Miller and Tigyi (Gupte et al. 
2011) that this is due to the propensity for hydrolysis of the amide bond, making S32826 
relatively unstable. In their own work Miller and Tigyi report a series of benzyl and 
naphthalene methyl phosphonic acid-derived compounds, of which 12 and 13 are most 
active, as inhibitors of autotaxin and that possess anti-invasive and anti-metastatic activity 
(Gupte et al. 2011). The synthetic approach to compound 12 (fig. 8) begins with a Heck 
coupling of the benzoic acid derivative to introduce the long alkyl side chain. 
Compound 12 shows 94.8% inhibition of autotaxin and has an IC50 of 0.17 µM, with a Ki of 
0.27 µM and displays a mixed mode of inhibition. In addition to inhibiting the invasion of 
MM1 hepatoma cells in vitro in a dose-dependent fashion, compound 13 significantly 
decreases lung metastasis of B16-F10 syngeneic mouse melanoma. Compound 12 has an 
average terminal half-life of 10  5 hours and causes a long-lasting decrease in plasma LPA 
levels. 
Prestwich has recently reported the synthesis of a hydroxylated S32826 analogue, (fig. 8,  
14), that retains acceptable levels of solubility (4mg/ml) whilst maintaining its potency as an 
inhibitor of autotaxin (Ki = 24.2 nM) and has potential for in vivo utility (Jiang et al. 2011). 
Compound 14 is currently undergoing further preclinical study. 
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Metabolically stable analogues of LPA, 15 and 16, were designed by Prestwich and co-
workers (Jiang et al. 2007). Compound 15 showed selective agonist activity for LPA2, 
whereas 16 is a selective antagonist of LPA4 and indeed is the first antagonist of this receptor 
to be reported. Compound 15 was found to be as effective as natural LPA as an inhibitor of 
autotaxin. Arguably the most interesting compound though, 16, showed pan-antagonism of 
LPA GPCR’s and was also active as an autotaxin inhibitor, thus having potential in 
anticancer and anti-metastasis models in cancer therapy (Zhang et al. 2009). 
 
 
Fig. 8. (i) Pd(OAc)2, Et3N, DMF, reflux, 16 h; (ii) LAH, THF, 0 oC-rt, 4 h; (iii) H2, Pd/C, 
MeOH, rt, 2 h; (iv) PBr3, Et2O, rt, 30 min; (v) P(OMe)3, reflux, 18 h; (vi) TMSBr, CH3CN, 
reflux, 1 h; (vii) MeOH, rt, 30 min. 
6. Structure of autotaxin and molecular modelling to aid drug design 
6.1 Autotaxin structure 
The availability of data describing the structure of autotaxin is a superb tool to support drug 
discovery. Of the 8 protein crystal structures of autotaxin (ENPP2) that have thus far been 
described (Hausmann et al. 2011; Nishimasu et al. 2011) only one (2XRG.pdb; Table 1) has a 
small drug-like molecule bound in the active site. There are two unliganded structures. The 
others contain a range of phospholipids and LPA analogues with a variety of fatty chains and 
LPA analogues. The overall architecture of autotaxin is shown in figure 9.  The N-terminus 
begins with a pair of somatomedin-B like (SMB) domains (residues 56-96 and 96-140) which 
lead into a phosphodiesterase domain (160-539) which contains a catalytic zinc binding site,  a 
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lasso loop (residues 539-590) and finally a nuclease domain (residues 539-862). It has also been 
suggested that a glycan chain located between the phosphodiesterase and nuclease domains is 
essential for correct folding of the protein. Strong bonding and electrostatic interactions are 
observed between the phosphodiesterase and the C-terminal region of the NUC domains 
including a disulphide cysteine bridge between residues 413 and 805 along with seven 
hydrogen bonds and nine salt bridges. This, combined with the extension of the Lasso loop 
from the PDE domain around the NUC domain, makes for a tight and well-ordered protein. 
 
PDB CODE Description Reference 
2XRG.pdb Rat ATX with ligand Hausmann  et al 
2XRN.pdb Rat ATX no ligand Hausmann  et al 
3NKM.pdb Mouse ATX Nishimasu  et al 
3NKN.pdb Mouse ATX 14:0 LPA Nishimasu  et al 
3NKO.pdb Mouse ATX 16:0 LPA Nishimasu  et al 
3NKP.pdb Mouse ATX 18:1 LPA Nishimasu  et al 
3NKQ.pdb Mouse ATX 18:3 LPA Nishimasu  et al 
3NKR.pdb Mouse ATX 22:6 LPA Nishimasu  et al 
Table 1. Structures of human autotaxin available in the Protein database. (www.pdb.org) 
 
 
Fig. 9. The domain structure of autotaxin. The figure shows the location of the somatomedin 
domain (SMB), the phosphodiesterase domain (PDE) containing the catalytic site, the lasso 
loop and the nuclease domain (NUC).  
The SMB domains are required for integrin binding and so may play a role in recruiting 
autotaxin to the cell surface where LPA receptors are located. A tunnel between one of the 
SMB domains and the ligand binding pocket has been suggested to facilitate delivery of 
LPA to cell surface receptors (Tabchy et al. 2011). The location of the tunnel compared to the 
catalytic site is shown in figure 10.  Many lipophilic molecules are transported bound to 
protein carrier, such as albumin, so it seems reasonable that the tunnel fulfils a carrier role.  
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Fig. 10. A. A cut away diagram of the hydrophobic channel (right) adjacent to the ligand 
binding pocket. The main features of the binding site are highlighted with ovals. B. A close-
up view of the local environment of catalytic zincs. The residues are coloured: grey, carbon; 
blue, nitrogen; red oxygen, light blue, zinc. 
6.2 Ligand binding site 
The overlay of several published X-ray structures of autotaxin shows a high conservation of 
ligand binding sites with only a few mobile residues. It is important to consider these as 
they may change the shape of the pocket or the electronic environment presented to the 
ligand and consequently affect ligand binding (fig 11). 
 
 
Fig. 11. A. The overlay of the active sites of 8 published protein structures of autotaxin. 
Residues whose positions have moved significantly between the structures are shown 
emboldened. Carbon atoms in LPA are shown in green whereas autotaxin carbon atoms are 
coloured grey; other atoms are coloured purple (phosphate), blue (nitrogen), red (oxygen) 
and light blue (zinc).  B. An annotated view of the main features of the ligand binding site 
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The main features of the catalytic site are shown in figure 11. There are two di-cationic zinc 
atoms (fig 10 and fig. 11). The first is fully co-ordinated with a histidine, and threonine and 
two aspartate residues. The second zinc ion is co-ordinated by an aspartate and two 
histidine residues, leaving it available for co-ordination by a further negatively charged 
species such as phosphate or carboxylate.  
Asn231 and Thr210 have been shown to be crucial for catalysis. These are located close to one 
zinc ions and provide a hydrogen bonding environment. Asn231 gives a preference for 
hydrogen bond acceptors while Thr210 provides an opportunity for irreversible (covalently 
bonded) ligands such as boronic acids to react. The conserved water that is held by 
hydrogen bonds between Asp311 and Glu308 can also play a role in control of ligand 
orientation and enantio-selectivity of ligand recognition. 
The remainder of the site consists of a large hydrophobic pocket which has recognition 
features for the lipophilic chain of LPA. Within this pocket most of the side chains appear to 
be less mobile, although there are however three notable exceptions,  Glu308, Phe274 and 
Arg244, some of which may help determine the potency with which ligands bind to 
autotaxin.  Movement of Glu308 seems to displace a water molecule.  Phe274 is mobile and 
unresolved in some structures but is shown to occupy various positions (fig. 12) in the 
hydrophobic pocket in others crystal structures in some cases moving to accommodate the 
ligand.  We speculate that movement of this residue allows LPA to move from the active site 
into the hydrophobic tunnel. Arg244 is also mobile but its location adjacent to the solvent 
suggests that it may not be as important for ligand recognition. 
 
 
Fig. 12. This diagram shows the movement of side-chain Phe274  (grey, in centre of diagram) 
within the ligand binding site. The green shows the bound boronic acid inhibitor. 
6.3 Docking methods 
We have used the published crystal structures in an effort to understand the activity of 
several of the compounds described in section 5.  In particular we evaluated whether the 
reported ligands were involved in zinc binding or whether they could occupy the 
hydrophobic pocket. Pharmacophoric overlay of autotaxin ligands has previously been 
reported to give a reasonable explanation of their relative binding modes by assuming that 
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the ligands all make the same interactions within the autotaxin pocket (North et al. 2010). 
Here, however, we have used docking models of the catalytic zinc pocket to identify and 
compare the interactions of reported inhibitors.   Ligands were placed within the binding 
pocket by aligning them with the pharmacophore map that had been overlaid onto the 
inhibitor bound in structure 2XRG. The steric requirements of the pocket were then used to 
refine our understanding of the activities of the ligands. 
The pharmacophore map of the active site was constructed based on the binding of the 
boronic acid inhibitor HA155 (fig. 13). Docking to this map was performed using MOE 
software from the Chemical Computing Group. The placements of ligands were constrained 
to pharmacophoric points within the active site and refinement was performed with the 
MMFF94x force field (Halgren 1996).  
The docking model faithfully reproduced the position of the ligand from 2xrg.pdb and its close 
analogues. This gives us confidence in the docking models used. While the pharmacophore 
map suggests a rich hydrogen bonding network around the ligand, most of the “linker” region 
of the ligands fail to interact with the pocket other than with a few hydrophobic contacts. The 
conserved nature of the ligands’ hydrogen bonding motif, as can be seen from previous 
pharmacophore modelling efforts (North et al. 2010), suggests that there may be unresolved 
water atoms which are located in the site (large blue spheres in fig. 13). 
 
 
Fig. 13. A Pharmacophoric map and shape of ligand from 2XRG.pdb which takes into 
account the steric and electronic requirements of the pocket when placing the ligand. (Blue 
Mesh= hydrogen bond acceptor projected points, Green Mesh=Hydrophobic areas, 
Brown/yellow Mesh=Aromatic centers) B. The zinc binding portion of molecule 5 after 
docking to the pharmacophore map in the binding site. 
The best fit to the zinc pocket was obtained for the carboxylic acid group from molecules 4 
and 5 which appear to satisfy all the steric and electronic requirements of the local pocket 
(Fig below) When the hydrophobic tail of the docked molecules is prevented from 
occupying the ligand binding pocket because of a lack of ligand flexibility, it is often placed 
by the docking software in the tunnel region of the protein.  This may be influenced by 
Phe274 which may act as a switch closing one or the other of these sites. Stabilization of this 
residue may contribute to ligand affinity. 
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Ligands which bind with high affinity interacted with both the zinc ion and also occupied the 
hydrophobic pocket e.g. with a benzyl group. In contrast, ligands which bind with low affinity 
failed to bridge the zinc ion and the hydrophobic portion of the ligand binding site. This leads 
us to conclude that for ligands to bind with high affinity, they should preferably bind both 
these sites. Docking studies also suggest that the hydrophobic tunnel provides an alternative 
location for ligands but these ligands identified so far fail to achieve better than micromolar 
activities.  These observations may be used to design improved autotaxin inhibitors. 
7. Potential clinical uses of autotaxin inhibitors 
Once inhibitors of autotaxin complete preclinical evaluation, how could these be evaluated 
in clinical trials? As we have discussed above, autotaxin may not be the only enzyme that 
contributes to the formation of LPA in ovarian cancer and so it is possible that inhibition of 
autotaxin may not elicit the desired therapeutic effect.  It will be important, therefore, to 
include in early clinical trials a measurement of the change in LPA in ascites following 
treatment with an autotaxin inhibitor and to establish biomarkers (e.g. measurement of 
autotaxin in ascites fluid) to stratify the patients which are likely to respond.  
The data we have reviewed also suggests a number of different settings in which autotaxin 
inhibitors could be used. Autotaxin inhibitors may be useful to inhibit the growth of 
primary tumors or to inhibit tumor cell migration, invasion and metastases. Clinical trials to 
evaluate these may differ somewhat, for example using different surrogate endpoints 
(tumor shrinkage versus decreased metastasis). Different schedules of drug administration 
may also be appropriate. To cause tumor cell death, relatively short term treatment with the 
drug may suffice, but suppression of metastasis may require prolonged treatment. This 
highlights the importance of considering the therapeutic goal that is being evaluated with an 
autotaxin inhibitor at the outset.  
As we have discussed, there is a large body of evidence indicating a role for LPA in cancer 
cell migration and invasion. In addition, several studies demonstrate in animal models of 
metastasis that inhibitors of autotaxin reduce colonization of the lung by tumors cells (Baker 
et al. 2006; Gupte et al. 2010; Gupte et al. 2011). Thus, one potential clinical use of autotaxin 
inhibitors is to inhibit metastasis. Unfortunately, many ovarian cancer patients present with 
advanced disease, and significant dissemination of the tumor within the peritoneal cavity 
has already taken place by the time of diagnosis. Although it may be beneficial to prevent 
further metastasis and progression to later stage disease, there may also be micro-metastases 
that are not evident on examination. It is not clear, then, whether inhibiting further 
metastasis would be helpful. Evaluation of autotaxin inhibitors as anti-metastatic agents in 
patients with early stage disease will also be challenging. Relatively few patients are 
diagnosed with early stage disease and these patients generally have a good prognosis, with 
90% of patients surviving more than 5 years. A large cohort of patients may also be required 
to ensure sufficient patients are evaluated who lack pre-existing micro-metastases but who 
will progress to more advanced disease. The cost of such a large and long trial may be 
prohibitive unless an alternative is found. 
We have also reviewed the substantial evidence linking LPA and autotaxin to cell 
survival.  Autotaxin inhibitors may have an indirect cytotoxic effect or inhibit the growth 
of primary (and secondary) tumors. This might reflect deprivation of LPA directly 
causing apoptosis of the tumor cells, or it might reflect a less supportive 
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microenvironment. In support of this approach, BrP-LPA  (Bromophosfono-
lysophosphatidic acid; 16, fig. 8) causes regression of breast tumor cells both in 3D in vitro 
models (Xu and Prestwich 2010) and as a xenograft (Zhang et al. 2009),  although as the 
authors clearly state, this drug is also a pan LPA receptor antagonist and its activity 
cannot be ascribed to inhibition of autotaxin alone. Also, over-expression of autotaxin is 
sufficient to induce breast cancer, suggesting that selective inhibition of autotaxin may be 
sufficient to cause regression of comparable tumor types. An alternative to using an 
autotaxin inhibitor as a single agent is to use it in combination with chemotherapy and 
this is supported by the data implicating autotaxin and LPA in chemoresistance that we 
have discussed. Clearly this strategy has potential in patients who have developed 
chemoresistant disease, but it may also be useful to increase the response in patients 
whose tumors are sensitive to chemotherapy. 
A pragmatic solution may be to evaluate autotaxin inhibitors first for their ability to inhibit 
tumor growth (either as a single agent or in combination with chemotherapy) and if this is 
successful evaluate their use as anti-metastatic agents after drug receives marketing 
approval. This may mitigate some of the risk associated with following a purely anti-
metastatic approach to drug development. 
 
 
Fig. 14. The hydrophobic “tail” in ligands may occupy the hydrophobic pocket or the 
hydrophobic tunnel and Phe274 divides the two hydrophobic ligand binding sites. 
8. Conclusion 
Our understanding of autotaxin, in terms of it biological function, its structure and its 
potential as a drug target in ovarian cancer is rapidly evolving. Several compounds are 
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currently undergoing preclinical discovery, and it cannot be long before the first of these 
enter clinic trials.  In this review, we have focused on the role of autotaxin in ovarian 
cancer, but it also plays a role in other cancer types as well as other pathophysiological 
conditions such as neuropathic pain. It seems plausible that autotaxin inhibitors will serve 
as new medicines and perhaps none of these applications is as exciting as the potential to 
treat drug-resistant ovarian cancer, a disease for which therapeutic options are currently 
limited. 
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